GE Di Cube
Total Consideration
$156.6M
Purchase-Price Allocation
Intangibles
$159.5M
Assets Acquired
$858.0K
Liabilities Assumed
$3.8M
LUNAI BIOWORKS, INC. — Key Metrics
12 years of history · ending 2023-06-30 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-1
Book Value Per Share
$1
Free Cash Flow Per Share
$-0
Cash Per Share
$0
Revenue Per Share
$-0
OCF Per Share
$-0
Return on Equity↓-55.8pts
-66.6%
Return on Assets↓-45.6pts
-55.5%
Return on Invested Capital↓-45.9pts
-51.1%
Debt to Equity
-0.16
Current Ratio↓-97.9% -$11
0.23
Quick Ratio↓-97.9% -$11
0.23
Asset Turnover
-0.00
Days Payables Outstanding
75266.67
R&D / Revenue
-3289.5%
SBC / Revenue
-2791.9%
Capex / Revenue
-23.5%
Working Capital↓-174.3% -$20M
$-8M
Net Current Asset Value↓-261.5% -$15M
$-9M
Invested Capital↓-73.1% -$127M
$47M
OCF / Net Income↓-37.2% -$0
0.30
FCF / Net Income↓-41.9% -$0
0.30
Accruals Ratio (Sloan)↓-42.6pts
-47.9%
Net Debt↑+84.7% +$10M
$-2M
Net Debt / EBITDA↓-95.7% -$1
0.05
Interest Coverage↑+100.0% +$256K
-66.44
Cash Coverage↑+100.0% +$198K
-20.29
Capex Coverage↓-3231.4% -$384
-395.46
Tangible Common Equity↓-78.4% -$127M
$35M
TCE / Total Assets↓-30.0pts
59.7%
Goodwill / Total Assets↑+13.5pts
20.0%
NOPAT↓-250.8% -$22M
$-30M
Cash ROIC↓-14.3pts
-19.8%
WC / Revenue
6679.6%
Capex / D&A↓-97.4% -$10
0.26
Reinvestment Rate↑+6.1pts
0.2%
Asset Growth vs Revenue Growth
172.6%
Book Value 5Y CAGR
-21.8%
Stock Price (FY-end)↓-87.4% -$39
$6
Market Cap
$319M
P/S Ratio
-2519.54
P/B Ratio
6.86
P/TB Ratio
9.16
Enterprise Value
$317M
EV / Sales
-2504.74
FCF Yield
-3.7%
Shareholder Yield
-1.1%
R&D Yield
1.3%
Capex Yield
0.0%
Shares Variation (YoY)
7.1%
Beta (5Y)↑+1105.1% +$1
1.02
Cost of Equity↑+4.7pts
9.6%
Cost of Debt (after tax)
1.8%
52W High↓-69.1% -$64
$29
52W Low↓-88.0% -$29
$4
Trailing Return 1Y↓-68.3pts
-76.1%
Trailing Return 5Y
-88.4%
F-Score (Piotroski)↑+100.0% +$1
2.00
Z-Score (Altman)
8.00
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Stock Price on Earnings Dates
LUNAI BIOWORKS, INC. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2012 | FY2013 |
|---|---|---|
| Federal Statutory Rate | -34.00% | -34.00% |
| State & Local Income Taxes | — | — |
| Foreign Rate Differential | — | — |
| Other Adjustments | — | — |
| Valuation Allowance Change | 34.00% | 34.00% |
| Effective Tax Rate | 0.00% | 0.00% |
Cash vs Accrual
| Item | FY2012 | FY2013 |
|---|---|---|
| Income Tax Expense (Accrual) | — | — |
| Income Taxes Paid (Cash) | — | — |
LUNAI BIOWORKS, INC. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Bio Symetricsnc Acquisition
Total Consideration
$6.1M
Purchase-Price Allocation
Intangibles
$6.0M
Assets Acquired
$26.9K
Liabilities Assumed
$82.4K